Regulatory approval

Published by the Health Service Executive. Approved

Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Quizartinib: CDS; Daunorubicin, Cytarabine: N/A

Citation

Quizartinib, DAUNOrubicin and Cytarabine Induction Therapy, 2026, version number 2, viewed 02/08/2026, https://healthservice.hse.ie/documents/7017/886_Quizartinib_Induction_DAUNOrubicin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib